SIGNALGENE INC has a total of 22 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Australia, Canada and EPO (European Patent Office). Its main competitors in its focus markets biotechnology and machines are GENPOINT AS, CERGENTIS B V and SINO GENO MAX CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 5 | |
#2 | Canada | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Machines |
# | Technology | |
---|---|---|
#1 | Measuring microorganism processes | |
#2 | Microorganisms | |
#3 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Rousseau Francois | 15 |
#2 | Malek Lawrence T | 4 |
#3 | Gee Mark | 2 |
#4 | Belouchi Abdel Majid | 2 |
#5 | Gauvreau Denis | 2 |
#6 | Fournier Helene | 2 |
#7 | Labuda Damian | 1 |
#8 | Sinnett Daniel | 1 |
#9 | Sooknanan Roy R | 1 |
Publication | Filing date | Title |
---|---|---|
WO0173116A2 | Method for determining osteoporosis susceptibility and/or low bone density and reagents therefor | |
EP1234028A2 | Preparation of sequence libraries from non-denatured rna and kits therefor | |
EP1114180A2 | Marker at the vitamin d receptor gene for determining breast cancer susceptibility | |
EP1114179A2 | Marker at the androgen receptor gene for determining breast cancer susceptibility | |
EP1114181A2 | Combination of markers at the estrogen- and vitamin d-receptor genes or equivalents thereof to prognose a response to osteoporosis therapy | |
WO0014273A2 | Differential genetic display technique and vector | |
US6498024B1 | Subtractive amplification kit useful in the diagnosis of genetic disease mutation or variation |